Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05869708 · ClinicalTrials.gov registry record · NA

PRISM Neurofeedback Training for MDD Anhedonic Patients

A NA study, sponsored by GrayMatters Health.

Completed
Registry status
NA
Development phase
19
Enrollment target

NCT05869708 is a NA study that has completed, run by GrayMatters Health. The registered enrollment target is 19 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05869708, a NA study, has completed, sponsored by GrayMatters Health.

COMPLETED
Registry status
NA
Development phase
19 participants
Enrollment target

Study Summary

The goal of this interventional double-blind study is to demonstrate the safety and efficacy of PRISM neurofeedback training within an MDD Anhedonia sample. The goals of this study include: 1. Demonstrating the safety and efficacy of Prism Neurofeedback training within an MDD Anhedonia sample; 2. Identifying clinical profile/symptoms-based biomarkers (e.g., Hamilton Depression Rating Scale - HDRS-21, Dimensional Anhedonia Rating Scale - DARS, Snaith-Hamilton Pleasure Scale for Clinicians SHAPS) scores that can be used by clinics to administer Prism therapy in conjunction with standard of care (SOC) therapy; 3. Producing initial guidelines for integrating Prism neurofeedback training for MDD therapy with MDD Anhedonia (SOC). Participants will be randomly assigned to one of two arms, Active, or Sham.

Interventions

  • DEVICE Active RS-EFP
  • DEVICE Sham RS-EFP

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2023-07-01
Est. Completion 2025-09-03
Phase NA

Sponsor

GrayMatters Health

4 total trials

What the Registry Record Tells You About NCT05869708

The ClinicalTrials.gov registry entry for NCT05869708 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GrayMatters Health, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Active RS-EFP is the first listed.

NCT05869708 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05869708 about?

NCT05869708 is a clinical study titled "PRISM Neurofeedback Training for MDD Anhedonic Patients". The goal of this interventional double-blind study is to demonstrate the safety and efficacy of PRISM neurofeedback training within an MDD Anhedonia sample. The goals of this study include: 1. Demonstrating the safety and efficacy of Prism Neurofeedback training within an MDD Anhedonia sample; 2. ...

What is the current status of trial NCT05869708?

This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2023-07-01. Estimated completion is 2025-09-03.

What interventions are being tested in trial NCT05869708?

The interventions under investigation include: Active RS-EFP (DEVICE), Sham RS-EFP (DEVICE).

Who is sponsoring clinical trial NCT05869708?

This trial is sponsored by GrayMatters Health, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.